Why does null hypothesis testing matter for neutralization assay target validation?

Null hypothesis testing in the neutralization assay quantifies whether observed reductions in viral entry are statistically significant, supporting robust target validation for antibody-mediated inhibition. This ensures that candidate antibodies or sera demonstrate true neutralizing activity beyond baseline variability. Such rigor underpins confidence in advancing immunotherapeutic leads.

How does independent variable isolation fit the pseudovirus neutralization workflow?

By controlling serum dilution and pseudovirus input, the assay isolates the effect of specific antibodies on viral entry, enabling mechanistic de-risking. This isolation clarifies the contribution of humoral immunity and informs early-stage candidate selection. It supports reproducible, interpretable outputs for cross-study comparison.

What do quantitative luminescence measurements enable in serum neutralization testing?

Quantitative luminescence readouts provide a direct, scalable measure of viral entry inhibition, allowing precise comparison of neutralizing activity across samples. These outputs facilitate statistical analysis and threshold setting for immune potency. They are essential for high-throughput screening and portfolio triage.

Why are replication requirements critical for cross-functional neutralization assay collaboration?

Replication ensures assay reproducibility and data reliability, which are vital for cross-team decision-making and downstream development. Consistent results across replicates support confidence in candidate advancement and facilitate regulatory and translational alignment. This underpins enterprise-wide assay adoption.

What statistical analysis capabilities are required before implementing pseudovirus neutralization assays?

Robust statistical analysis is needed to interpret luminescence data, determine neutralization thresholds, and validate assay performance. Capabilities should include calculation of percent neutralization, curve fitting, and significance testing. These analyses support data-driven advancement decisions in immunotherapy pipelines.

Nötralizasyon Testi Yoluyla SARS-CoV-2'ye Karşı Humoral İmmün Yanıtları İzlemek İçin Moleküler Bir Araç Olarak Psödotiplenmiş Virüsler

2.9K görüntüleme

05:49 dk

21 Kasım 2023

10.3791/65658-v

21 Kasım 2023

2.9K görüntüleme

Tobia Fantoni^*¹ , Michele Bissoli^*¹ , Chiara Stefani¹ , Mauro Voi¹ , Alexandrina Dabija¹ , Rebecca Casula¹ , Domenico Luca Minafra¹ , Julys da Fonseca Palmeira² , Enrique Roberto Argañaraz² , Martin Mayora-Neto³ , Nigel J. Temperton³ , Donato Zipeto¹ , Alessandra Ruggiero¹

¹Department of Neuroscience, Biomedicine and Movement, University of Verona, ²Laboratory of Molecular Neurovirology, Faculty of Health Science, University of Brasília, ³Viral Pseudotype Unit, Medway School of Pharmacy, Universities of Kent and Greenwich at Medway

^* These authors contributed equally

Psödotipli virüsler (PV'ler), otantik virüsleri işlemekten daha güvenli koşullar altında konak-virüs etkileşimlerini incelemek için kullanılan replikasyon kusurlu virionlardır. Burada, SARS-CoV-2 PV'lerin COVID-19 aşılamasından sonra hastaların serumunun nötralize edici yeteneğini test etmek için nasıl kullanılabileceğini gösteren ayrıntılı bir protokol sunulmaktadır.